SinUse Corp.

We are thrilled and honored to announce that we have been selected as one of the top finalists for the Golden Ticket Pitch competition by @University Lab Partners in partnership with @Allergan Aesthetics. We are excited to participate in the Demo Day, where we will pitch our groundbreaking ideas to an esteemed panel of industry experts, investors, and entrepreneurs. Join us at the Demo Day on Thursday, August 29th! https://lnkd.in/gUxdaw2r?

?? Hello Nucleate LA Family! ?? This last Monday, we held our Final Pitch showcase for our third Activator cohort. Firstly, thank you! Without our incredible supporters from all over Los Angeles, there would be no showcase to begin with. We’ve had many returners and first-timers to this year’s demo day, and we hope to see everyone in future showcases! ?? Secondly, we'd like to give a shoutout to the experts and mentors that have worked to prepare our teams for their pitches. We'd also love to thank our judges Cynthia McKee, PhD, Tari Suprapto, and Han Lee for supporting our work as well. ?We'd also love to give a shoutout to our HQ Platinum sponsors (Eli Lilly and Company, Genentech, Pillar VC, Alnylam Pharmaceuticals, BlueYard Capital, and MilliporeSigma) and our regional sponsors (Magnify Incubator, Biocom California, Moore-Hufstedler Fund, LA BioSpace, and BioscienceLA)! ?? Lastly, but certainly not least, we’d like to thank our incredible Activator teams. From medicine to business, we’ve had the opportunity to interact with brilliant players from all over the biotech ecosystem. We’re excited to see where their journey heads next and we’ll always be rooting them on! Checkout the below list for a summary of the winning teams this year. ? Los Angeles Activator 1st Place: Osteoleap Therapeutics ?? MilliporeSigma Regional High Impact Culture Award: Syntaxa ?? Genentech Regional Diversity, Equity, and Inclusion Prize: Syntaxa ?? Alnylam Pharmaceuticals Regional Scientific Excellence Award: Saku Biosciences ?? While this marks the end of this year's Activator cycle, this won’t be the last you’ll be hearing or seeing from us. Join us at the Nucleate Alumni Summit later this Summer by following our HQ page to stay updated. And if you're interested in getting involved with our chapter, feel free to reach out!

It was my pleasure to attend #LABEST2024 and to participate in the excellent panel with outstanding colleagues. Great energy and enthusiasm for innovation in Southern California and at #UCLA.

SinUse Corp. pitched at Nucleate Los Angeles. Thanks to our mentors along the way Chinmay Kanuga, Lusine (Lucy) Abgaryan, PhD, MBA and Ahmed Zobi, EMBA. Big shoutout to the organizers Bryan Gerber and Arielle Hogan and all the people who helped us during this program.

SinUse Corp. attended the 2024 MedTech Innovator Road Tour in Los Angeles.

SinUse Corp. has advanced to the final round of the 2024 UCLA Anderson School of Management Innovation Challenge. Our team will be pitching on May 3rd!

SinUse Corp. was honored to be among the top 15% of companies chosen to participate in the MedTech Innovator pitch event in Los Angeles. This prestigious event provided us with a platform to present our pioneering approach to soft tissue reconstruction and to network with leading experts in the medical technology field. The experience was incredibly rewarding, featuring enriching interactions with fellow entrepreneurs from around the world and receiving valuable feedback from a knowledgeable panel of judges, which included distinguished members of the American Society of Plastic Surgeons (ASPS). These exchanges and new connections have greatly intensified our enthusiasm and commitment to our mission. At SinUse Corp., we are dedicated to revolutionizing fat grafting for soft-tissue reconstruction. Our focus is on developing fat implants for patients who have suffered soft-tissue loss due to brain and ENT cancers. Our mission goes beyond that and will also benefit breast reconstruction procedures in the near future. Looking ahead, the possibilities for SinUse Corp. are limitless. We are eager about the future and remain dedicated to leading the charge in soft-tissue reconstruction technology.